Core Viewpoint - WuXi Biologics (02269.HK) announced the issuance of 3 million shares due to the exercise of stock options on November 14, 2025 [1] Summary by Category - **Company Announcement** - WuXi Biologics will issue 3 million shares as a result of stock option exercises [1]

Core Viewpoint - WuXi Biologics (02269) announced the issuance of 3 million shares on November 14, 2025, due to the exercise of options, with an issue price of HKD 1.29 per share [1] Company Summary - The company will issue a total of 3 million shares [1] - The exercise price for the shares is set at HKD 1.29 each [1] - The issuance is scheduled for November 14, 2025, indicating a future financial event for the company [1]

Core Viewpoint - WuXi Biologics (02269) announced the issuance of 3 million shares on November 14, 2025, due to the exercise of options, with an issue price of HKD 1.29 per share [1] Summary by Category - **Company Actions** - WuXi Biologics will issue 3 million shares as a result of option exercises [1] - The issue price for the shares is set at HKD 1.29 each [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： WuXi Biologics (Cayman) Inc. 藥明生物技術有限公司*（於開曼群島註冊成立的有限公司）*僅供識別 呈交日期： 2025年11月14日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02269 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發 ...

Group 1 - WuXi Biologics (02269) announced the issuance of a total of 8.5314 million ordinary shares as part of the exercise of options under its pre-IPO share option plan adopted on January 5, 2016, and revised on August 10, 2016 [1]

Core Viewpoint - WuXi Biologics (02269) announced the issuance of a total of 8.5314 million ordinary shares as part of the exercise of options under its pre-IPO share option plan adopted on January 5, 2016, and revised on August 10, 2016 [1] Summary by Category - **Company Actions** - The company has exercised options leading to the issuance of 8.5314 million ordinary shares [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： WuXi Biologics (Cayman) Inc. 藥明生物技術有限公司*（於開曼群島註冊成立的有限公司）*僅供識別 呈交日期： 2025年11月13日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02269 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | ...

Core Viewpoint - WuXi Biologics (02269) announced the issuance of 7.5 million ordinary shares on November 12, 2025, as part of the exercise of options under its pre-IPO share option plan adopted on January 5, 2016, and revised on August 10, 2016 [1] Summary by Relevant Sections - Share Issuance Details - The company will issue 7.5 million ordinary shares [1] - This issuance is related to the exercise of options under a previously established share option plan [1] - Historical Context - The share option plan was initially adopted on January 5, 2016, and revised on August 10, 2016 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： WuXi Biologics (Cayman) Inc. 藥明生物技術有限公司*（於開曼群島註冊成立的有限公司）*僅供識別 呈交日期： 2025年11月12日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02269 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發 ...

Core Viewpoint - WuXi Biologics (02269) announced the issuance of a total of 4.52 million shares due to the exercise of options on November 11, 2025 [1] Summary by Category - **Company Actions** - The company will issue 4.52 million shares as a result of option exercises [1]